New Zealand markets closed

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.0000-0.1300 (-6.10%)
At close: 04:00PM EDT
1.9300 -0.07 (-3.50%)
After hours: 05:40PM EDT

Plus Therapeutics, Inc.

4200 Marathon Boulevard
Suite 200
Austin, TX 78756
United States
737 255 7194
https://plustherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees20

Key executives

NameTitlePayExercisedYear born
Dr. Marc H. Hedrick M.B.A., M.D.President, CEO & Director945.34kN/A1963
Ms. Desiree SmithCorporate Controller, Principal Financial & Accounting OfficerN/AN/A1964
Dr. John K. FraserChief ScientistN/AN/A1961
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Corporate governance

Plus Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.